Chemoradiotherapy toxicity (CRT)

"Chemoradiotherapy toxicity" is not the name of a specific molecule or receptor. Instead, it refers to the spectrum of adverse effects that arise from the combined use of chemotherapy and radiation therapy in cancer treatment. This term encompasses both the individual toxicities associated with each modality as well as their potential additive or synergistic harmful effects on normal tissues. Toxicities can be acute (occurring during or shortly after treatment) or late (developing months to years later), affecting various organs such as the heart, skin, gastrointestinal tract, liver, kidneys, lungs, blood cells/bone marrow and nervous system[1][3][4][5]. The severity and type depend on factors like drug regimen used in chemotherapy; radiation dose/location; patient health status; timing/sequencing of therapies; and underlying frailty[2][3]. "Chemoradiotherapy toxicity" is therefore not a therapeutic target but rather an important clinical consideration in oncology practice. There is something wrong with this target entry because it does not refer to any single molecule/receptor/protein/gene but instead describes an adverse effect phenomenon related to cancer treatments. It should not be classified as a molecular target.

Other names

Chemoradiation toxicityChemoradiotherapy-related toxicityCRT toxicityCombined modality therapy toxicity